LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms LEEomic
- Sponsors Novartis Pharmaceuticals
- 05 Aug 2019 Planned End Date changed from 3 Apr 2019 to 30 Dec 2019.
- 05 Aug 2019 Planned primary completion date changed from 2 Apr 2019 to 28 Dec 2019.
- 05 Aug 2019 Status changed from not yet recruiting to recruiting.